A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety and Pharmacokinetics of CHI-936 in Healthy Participants
This is a randomized, double-blinded, placebo-controlled, multiple-dose study is to evaluate the safety, tolerability, and PK of CHI-936 in healthy participants.
10607410 CANADA INC. DBA Spectrum Therapeutics
40 participants
Dec 2, 2019
Interventional
Conditions
Summary
CHI-936 is a standardized cannabis extract in an oil preparation that contains an approximate 20:1 ratio of CBD to THC (20 mg/mL CBD and < 1 mg/mL THC). At present, regulatory approvals, physician acceptance, and the utilization of CHI-936 in Phase 2/3 clinical trials for specific indications are hampered by the absence of critical Phase 1 data regarding its safety, tolerability, and pharmacokinetic (PK) profile. Therefore, the aim of this randomized, double-blinded, placebo-controlled, multiple-dose study is to evaluate the safety, tolerability, and PK of CHI-936 in healthy participants.
Eligibility
Inclusion Criteria8
- Is a healthy male or female adult aged 18–55 years at the time of screening.
- Has a minimum of 2 lifetime exposures to THC-containing cannabis products.
- Has a body mass index between 18 and 30 kg/m2.
- Is judged by the Investigator to be in generally good health at screening based on the results of a medical history, physical examination, 12-lead ECG, and clinical laboratory test results. Laboratory results outside of the reference range deemed to be acceptable will be documented as not clinically significant at the discretion of the Investigator.
- For women of childbearing potential, has a negative serum pregnancy test (ß-human chorionic gonadotropin [hCG]) at the Screening Visit and a negative urine pregnancy test at intake to the inpatient research facility.
- Agrees to abide by all study restrictions and comply with all study procedures.
- Must be adequately informed of the nature and risks of the study and give written informed consent prior to screening.
- Is, in the Investigator’s opinion, reliable, able, and willing to comply with all protocol requirements and procedures (including scheduled visits and confinement periods).
Exclusion Criteria20
- Women who are pregnant, lactating, breastfeeding, or planning a pregnancy.
- Women of childbearing potential, or men who are sexually active with a woman of childbearing potential, who are unwilling or unable to use an acceptable method of contraception (abstinence or the use of a highly effective method of contraception, including hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, vasectomy, or intrauterine device) from at least 21 days prior to the first dose of study medication until 28 days after the last dose of study medication. Participants with same sex partners do not require contraception.
- Has a history of epilepsy.
- Has used tobacco/nicotine-containing products on more than 5 occasions within 1 month of the Screening Visit or during the study.
- Has used any prescription drugs or herbal supplements (except hormonal contraception) within four weeks prior to the Screening Visit, unless approved by the Investigator and stable for at least 4 weeks prior to Screening through the final study visit.
- Use of any over-the-counter drugs, vitamins, or supplements within 72 hours prior to the first dose of study medication.
- Has or has previously had a positive result for the presence of Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibodies (HCVAb), or human immunodeficiency virus (HIV) antibodies.
- Has a positive breath test for ethanol or a positive urine screen for cocaine, THC, barbiturates, amphetamines, methamphetamines, benzodiazepines, methylenedioxymethamphetamine, phencyclidine, methadone, or opiates at the Screening Visit or prior to study treatment.
- Has a history of psychosis or schizophrenia, including among first-degree relatives.
- Any clinically significant condition or abnormal finding at the Screening Visit that would, in the opinion of the Investigator, preclude study participation or interfere with evaluation of the study treatment.
- Has a history of a known significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to cannabis, including phytocannabinoids and cannabinoid analogues, or excipients utilized within the IMP.
- Has taken grapefruit products and/or Seville oranges within the 7 days prior to dosing with study medication or during the study.
- Is taking a prohibited medication including warfarin, clobazam, valproic acid, phenobarbital, mTOR inhibitors, oral tacrolimus, and St. John’s Wort within 30 days of the Screening Visit or during the study.
- Has used cannabis, synthetic cannabinoid or cannabinoid analogues (e.g., dronabinol, nabilone), hemp products, synthetic cannabinoid receptor agonists (e.g., spice, K2), or any CBD- or THC-containing product (e.g., Sativex, Epidiolex) within 8 weeks of the Screening Visit or during the study.
- Has a history of treatment for or exhibits evidence of alcohol or drug abuse within the past year or regular alcohol consumption exceeding an average of 2 units of alcohol per day.
- Has a history or current diagnosis of a significant psychiatric disorder that would, in the opinion of the Investigator, affect the subject’s ability to comply with the study requirements.
- Has a history of suicidal behavior or any active suicidal ideation as indexed by endorsement of questions #4 or #5 on the C-SSRS.
- Has suspected or confirmed cardiovascular disease.
- Has participated in any investigational product or device study within 30 days prior to the Screening Visit, or is scheduled to participate in another investigational product or device study during the course of this study.
- Demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This is a Phase 1a, randomized, double-blind, placebo-controlled, multiple-dose study to assess the safety, tolerability, and PK of CHI-936 versus placebo in healthy male and female participants ages 18–55 years. The study will enroll 40 participants (8 participants per group; 4 active treatment groups and 1 placebo group). During the Treatment Period, participants will be randomized in a 1:1:1:1:1 ratio to 1 of 5 treatment groups: • Treatment A: 120 mg total CBD and 5.4 mg total THC daily (3 mL CHI-936 and 15 mL placebo, twice daily) • Treatment B: 240 mg total CBD and 10.8 mg total THC daily (6 mL CHI-936 and 12 mL placebo, twice daily) • Treatment C: 360 mg total CBD and 16.2 mg total THC daily (9 mL CHI-936 and 9 mL placebo, twice daily) • Treatment D: 480 mg total CBD and 21.6 mg total THC daily (12 mL CHI-936 and 6 mL placebo, twice daily) • Treatment E: Placebo (18 mL placebo, twice daily). Treatment will be administered every 12 hours orally. CHI-936 is a cannabis oil that contains an approximate 20:1 ratio of CBD to THC (20 mg/mL CBD and < 1 mg/mL THC). The intervention (i.e. treatment with IMP) will be 7 days and will monitored and documented during inpatient stay.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12619001450101